Not So Different: Steven C. Hill, PhD, Discusses Rebates and Specialty Drug Spending
November 8th 2020In an interview with The Center for Biosimilars®, Steven C. Hill, PhD, a senior economist with the Agency for Healthcare Research and Quality, discusses a recent study he co-authored on specialty drug spending.
Not So Different: Nancy Globus, PharmD, on Whether Comparative Efficacy Trials are Necessary
October 25th 2020We spoke with Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs, for her take on requirements for comparative efficacy trails and whether they add meaningful data for the purposes of biosimilar acceptance.
Wayne Winegarden, PhD, on Downside of Importing Drugs From Canada
October 4th 2020We sat down with Wayne Winegarden, PhD, a senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI's Center for Medical Economics and Innovation, to discuss why the FDA’s implementation of the Safe Importation Action Plan is controversial.
Not So Different: Alex Moulson on How Companies Choose Which Biosimilars to Produce
September 13th 2020We sat down with Alexandra Moulson, vice president of Strategy, Programs, and Portfolio at Polpharma Biologics to discuss how Polpharma Biologics and other contract development and manufacturing organization (CDMOs) function and how companies choose which molecules to develop.
Cheryl Larson on How Employers Can Get Biosimilars Added to Their Health Plan
September 6th 2020We sat down with Cheryl Larson, president and CEO of Midwest Business Group on Health (MBGH), an employer coalition based in Chicago, Illinois, to discuss the current obstacles employers face in getting biosimilars added to their formularies and what steps they can take to get around them.
Nancy Globus, PharmD, on the Effect of Biosimilar Suffixes
August 23rd 2020We sat down with Nancy Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs (ACMA), to discuss the true impact that suffixes have on biosimilar perception and whether they are appropriate for the United States.
Carter Thorne, MD, Discusses Biosimilar Switching in Canada
August 16th 2020We sat down with Carter Thorne, MD, FRCPC, former president of the Canadian Rheumatology Association and chief of the Division of Rheumatology and director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Ontario, to discuss the current status of Canada’s comfort level with biosimilars and what he sees for the future of switching policies.
Sizing Up European Biosimilar Competition
August 9th 2020We sat down with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, to discuss their scorecard report for biosimilar access and what European markets they feel need the most work.
Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation
August 2nd 2020We sat down with Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmaceuticals and co-chair of the Biosimilars Forum education committee, to discuss what more needs to be done to combat biosimilar misinformation and how patients and physicians can help the cause.
Rathore: What Biosimilar Developers Can Learn From Application Failures
July 26th 2020We sat down with Anurag Rathore, PhD, lead author of the study and coordinator of the Center of Excellence for Biopharmaceutical Technology in Delhi, India, to discuss the findings from this study and how biosimilar corporations can learn from them.
Byoungseo Choi on Celltrion's Biosimilar Goals For 2030
July 19th 2020We sat down with Byoungseo Choi, the head of marketing for Celltrion Healthcare, to discuss exactly how this plan is going to work, the company’s current biosimilar pipeline, and its expectations for how their products will perform.
Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization
July 12th 2020We sat down with Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare, to discuss how this program has empowered biosimilar utilization within Emory and how Emory’s initiatives could be implemented on a larger scale.
Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins
July 5th 2020We sat down with Jing Chao, MD, an assistant professor of medicine and metabolism, endocrinology and nutrition at the University of Washington in Seattle and one of the lead investigators of this study to discuss the findings of this study as well as how biosimilar insulins could pave the way for increased patient access.
Joe Fuhr, PhD, Discusses His Predictions for the Growing Biosimilar Market
June 28th 2020We sat down with Joe Fuhr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics to discuss the current state of the biosimilar landscape and what he sees going forward.
Nick Mitrokostas Discusses New Biosimilar Approval and the Outlook for 2020
June 21st 2020In this episode of Not So Different, we sat down with Nick Mitrokostas, an intellectual property (IP) lawyer and partner at Goodwin's IP Litigation group, to discuss how the approval of Pfizer’s pegfilgrastim biosimilar (Nyvepria) will affect the biosimilar market and what he sees for the rest of 2020.
Christine Simmon Discusses AAM Efforts for Biosimilar Legislation
June 14th 2020We sat down with Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the AAM, to discuss some of the advocacy changes the organization is looking to advance and their chances of approval.
Biosimilar Law Experts Discuss Potential Bills and Chances for Passage
June 7th 2020We sat down with Ha Kung Wong, an intellectual property law attorney and partner at Venable Fitzpatrick in New York and April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, to discuss potential bills to improve biosimilar uptake and their chances for passage.
April Breyer Menon Discusses 2 Potential Bills to Aid Biosimilar Uptake
May 28th 2020April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, discussed 2 pieces of legislation that have the potential to address barriers to biosimilar market entry including the Hatch-Waxman Integrity Act and the Stop Stalling Act.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
"Not So Different": Employers Advocate for Lower Drug Costs Through Biosimilars
January 13th 2020With pharmaceutical spending at record levels, employers are looking for solutions and are hopeful that biosimilars can play a role in controlling costs. On this episode, we speak with representatives of EmployersRX, a new coalition made up of 3 employer groups that are advocating for measures that would provide relief for the largest purchasers of healthcare.
"Not So Different": Goodwin Attorneys Give a Look at Biosimilar Litigation
January 5th 2020In the past decade of experience with the Biologics Price Competition and Innovation Act, a number of questions about the biosimilar pathway have been resolved through litigation. This week on the podcast, we're speaking with attorneys Robert Cerwinski, JD, and Alexandra Valenti, JD, both of whom are partners at Goodwin, about experience with litigation, the road ahead for biosimilars, and Goodwin's recently published guide to biosimilar litigation.